Ceribell, Inc. (CBLL)

Over the past six months, Ceribell's stock price has been impacted by several events. The FDA granted 510(k) clearance for its delirium monitoring solution, leading to a 5.4% rise in shares. Ceribell received FDA Breakthrough Device Designation for its LVO stroke detection solution. The company also received FDA 510(k) clearance for its Clarity algorithm for neonates. Ceribell reported its Q4 and full-year 2025 financial results, with revenue increases but a net loss, leading to a slight share decline. Analyst ratings remained positive, with a consensus rating of "Moderate Buy". Ceribell insiders have sold more company stock than they have bought. CBLL underperformed the US market but exceeded the US Medical Equipment industry over the past year.

The provided search results do not contain explicit information regarding the demand seasonality for Ceribell, Inc.'s products and services. Demand might be relatively stable throughout the year, driven by ongoing healthcare needs rather than seasonal fluctuations. The company's revenue growth is primarily attributed to the expansion into new accounts and continued adoption within its active account base, suggesting a consistent demand for its solutions.

Ceribell, Inc. is a healthcare technology company specializing in automated newborn hearing screening devices and point-of-care EEG platforms. The company's core mission is to transform the diagnosis and management of patients with serious neurological conditions. Ceribell's major products and services include the Ceribell System, disposable headbands and headcaps, a pocket-sized recorder, the Clarity AI-powered Seizure Detection Algorithm, an EEG Portal, and automated newborn hearing screening devices. The Clarity algorithm received FDA 510(k) clearance for detecting electrographic seizures from pre-term neonates through adults.

Ceribell, Inc. has a global presence through direct sales and distribution partnerships across North America, Europe, and select international markets. The company is headquartered in Sunnyvale, California, and the Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S.

Ceribell's brand reputation has been positively influenced by its advancements in medical technology and regulatory achievements. FDA clearances and designations for its delirium monitoring solution, Clarity algorithm, and LVO stroke detection have enhanced its standing as a leader in AI-based neuro monitoring. Strong revenue growth in 2025, driven by expansion into new accounts and increased adoption, suggests a positive reception of its products and services. The company has received a "Moderate Buy" consensus rating from analysts, indicating confidence in its future prospects.

Ceribell, Inc. has a significant number of institutional owners, with 156 institutional owners and shareholders holding a total of 29,264,733 shares. Major institutional owners include TPG GP A, LLC, FMR LLC, Red Tree Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Xingjuan Chao, Co-Founder, President, CEO, and Director, directly holds 1.9% of the total shares outstanding as of August 2025 and 2.74% as of March 2026. Josef Parvizi is also a Co-Founder, Chief Medical Advisor, and Director. Insiders hold 20.10% of the stock, and the general public owns an 11% stake.